Bayer/Onyx Nexavar Extends Life In Rare Thyroid Cancer
This article was originally published in The Pink Sheet Daily
Regulatory filings will be based on results of the Phase III DECISION trial reported at ASCO showing a near double progression-free survival advantage compared to placebo; no further overall survival analyses will be done because of crossover.
You may also be interested in...
Adding indications for Nexavar is critical to Bayer HealthCare’s plan to become a major global player in cancer therapeutics, Bayer oncology leader says at ASCO.
Onyx has learned a lot in its almost twenty year history with Bayer, managing through the upside and downside of having a Big Pharma partner.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.